ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

Low Total Cholesterol Linked To Higher Risk Of Cancer; Higher HDL Associated With Decreased Risk Of Cancer

November 27, 2009

To Review Cancer Bioinformatics Grid

November 12, 2010

NCI Grant Boosts UCLA Bladder Cancer Project

October 25, 2002

In Brief: Gregory Curt Nominated DCT Deputy DCC Seeks Occupational Cancer, Prevention Branch Chiefs

October 26, 1984

Armstrong Foundation To Fund Studies In Testicular Cancer

April 17, 1998

New Research Grant Awards

October 18, 1974